The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IGC | -4.53% | -69.84% | -21.31% | -99% |
| S&P | +16.23% | +94.45% | +14.22% | +423% |
IGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
A closer look at why most weed stocks went up in smoke despite Canada legalizing recreational cannabis.
From smoking-hot marijuana stock to smoldering mess in about a month.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.33M | 20.6% |
| Gross Profit | $0.03M | 28.6% |
| Gross Margin | 8.23% | 0.5% |
| Market Cap | $24.38M | -25.7% |
| Market Cap / Employee | $0.35M | 0.0% |
| Employees | 70 | 4.5% |
| Net Income | -$1.60M | 32.8% |
| EBITDA | -$1.76M | 21.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.45M | -75.1% |
| Accounts Receivable | $0.09M | 210.7% |
| Inventory | 1.4 | -11.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.14M | -31.7% |
| Short Term Debt | $0.07M | -52.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -68.43% | 32.9% |
| Return On Invested Capital | -89.14% | -16.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.42M | 20.9% |
| Operating Free Cash Flow | -$1.41M | 19.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.10 | 3.49 | 3.56 | 3.91 | -1.07% |
| Price to Sales | 27.43 | 21.10 | 18.14 | 19.15 | -35.63% |
| Price to Tangible Book Value | 5.24 | 4.62 | 5.08 | 5.53 | 8.98% |
| Enterprise Value to EBITDA | -19.57 | -15.08 | -17.89 | -14.26 | 5.84% |
| Return on Equity | -117.1% | -115.1% | -104.3% | -90.9% | -27.99% |
| Total Debt | $0.31M | $0.27M | $0.24M | $0.21M | -39.88% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
